查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1522304

2024 年前列腺癌核子医学诊断全球市场报告

Prostate Cancer Nuclear Medicine Diagnostics Global Market Report 2024
出版日期: | 出版商: The Business Research Company | 英文 175 Pages | 商品交期: 2-10个工作天内

价格
简介目录

前列腺癌核医诊断市场规模预计未来几年将快速成长。到2028年，这一数字将以14.8%的年复合成长率(CAGR)增长至14.9亿美元。预测期内的成长受到多种因素的推动，包括前列腺癌盛行率上升、对正子断层扫描的需求增加、环境永续性意识增强、癌症发生率增加以及持续的数位转型。这段时期预计的主要趋势包括产品创新、技术进步、核子医学扫描术诊断的进步、放射性药物和影像方式的改进以及创新放射性药物的开发。

随着摄护腺癌盛行率预计将增加，摄护腺癌核医学诊断市场预计将扩大。前列腺癌是一种始于前列腺的癌症，受到老龄化、生活方式改变和遗传倾向等因素的影响。前列腺癌的核子医学诊断提供了重要的见解，使临床医生能够为患者提供更准确、更有效的个人化治疗。例如，2024 年 1 月，美国癌症协会报告约有 299 万前列腺癌新病例，并有 35,250 人因此病死亡。此外，2021 年，美国癌症研究所记录每 10 万名男性中有 116.5 例新病例。因此，摄护腺癌盛行率的增加是摄护腺癌核医学诊断市场的关键驱动因素。

前列腺癌核医学诊断领域的主要企业正在积极创新诊断影像技术并获得美国食品药物管理局（FDA）的批准。 FDA 的许可确保医疗保健提供者和患者能够针对各种医疗状况获得安全有效的诊断测试。例如，2022年3月，瑞士製药公司诺华宣布推出Pluvic®（镥Lu 177 vipivotide tetraxetan），用于治疗诊断为表达前列腺特异性膜抗原阳性（PSMA阳性）的转移性去势抗性前列腺癌（mCRPC ）的成年患者。 Pluvicto 将标靶化合物（配体）与治疗性放射性同位素结合，为表达 PSMA 的前列腺癌细胞提供精确的癌症治疗。

目录

第一章执行摘要

第二章 市场特点

第三章 市场趋势与策略

第四章宏观经济情景

  • 高通膨对市场的影响
  • 乌克兰与俄罗斯战争对市场的影响
  • COVID-19 对市场的影响

第五章世界市场规模与成长

  • 全球前列腺癌核医诊断市场：驱动因素与限制因素
    • 市场驱动因素
    • 市场限制因素
  • 全球前列腺癌核医诊断市场表现：规模与成长，2018-2023
  • 全球前列腺癌核医诊断市场预测：规模与成长，2023-2028 年、2033 年

第六章 市场细分

  • 全球前列腺癌核医诊断市场：按类型、表现和预测，2018-2023、2023-2028、2033
  • 单光子发射电脑断层扫描 (SPECT)
  • 光子发射电脑断层扫描 (PET)
  • 全球前列腺癌核医学诊断市场：按测试类型分類的表现和预测，2018-2023、2023-2028、2033
  • 初步测试
  • 确认测试
  • 全球前列腺癌核医诊断市场：最终使用者的表现与预测，2018-2023、2023-2028、2033
  • 医院
  • 诊所
  • 其他最终用户

第 7 章 区域/国家分析

  • 全球前列腺癌核医诊断市场：按地区、表现及预测，2018-2023年、2023-2028年、2033年
  • 全球前列腺癌核医诊断市场：依国家、绩效及预测，2018-2023、2023-2028、2033

第八章亚太市场

第九章 中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第14章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章 义大利市场

第20章 西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章加拿大市场

第26章 南美洲市场

第27章 巴西市场

第28章 中东市场

第29章 非洲市场

第三十章 竞争格局及公司概况

  • 摄护腺癌核医诊断市场：竞争格局
  • 前列腺癌核医诊断市场：公司简介
    • Cardinal Health
    • General Electric
    • Bayer AG
    • Novartis AG
    • Siemens Healthineers AG

第三十一章 其他重大及创新企业

  • GE Healthcare
  • Lantheus
  • CURIUM PHARMA
  • Telix Pharmaceuticals Ltd.
  • Eckert & Ziegler AG
  • Point Biopharma Global Inc.
  • Point Biopharma
  • Alliance Medical Ltd.
  • SHINE Medical Technologies LLC
  • PETNET Solution
  • NorthStar Medical Radioisotopes LLC
  • Global Medical Solutions LLC
  • Isotope Technologies Garching（ITG）
  • Jubilant Pharma Limited
  • Blue Earth Diagnostics Inc.

第32章竞争基准化分析

第 33 章. 竞争对手仪表板

第三十四章 重大併购

第35章前瞻性与潜力分析

第36章附录

简介目录
Product Code: r18457

Prostate cancer nuclear medicine diagnostics involve the utilization of radioactive substances to detect and assess prostate cancer. These diagnostics play a crucial role in the detection, staging, and management of prostate cancer by providing comprehensive functional information regarding the disease's extent and characteristics. The process entails introducing radioactive substances (radiopharmaceuticals) into the body, typically through injection, which emit gamma rays or positrons.

The primary types of prostate cancer nuclear medicine diagnostics include single photon emission computed tomography (SPECT) and positron emission tomography (PET). Single photon emission computed tomography (SPECT) is a nuclear imaging technique that generates detailed three-dimensional images depicting the body's functional processes. These diagnostics encompass various test types, including preliminary and confirmatory tests, and are utilized by various end-users such as hospitals, clinics, and others.

The prostate cancer nuclear medicine diagnostics market research report is one of a series of new reports from The Business Research Company that provides prostate cancer nuclear medicine diagnostics market statistics, including prostate cancer nuclear medicine diagnostics industry global market size, regional shares, competitors with a prostate cancer nuclear medicine diagnostics market share, detailed prostate cancer nuclear medicine diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the prostate cancer nuclear medicine diagnostics industry. This prostate cancer nuclear medicine diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prostrate cancer nuclear medicine diagnostics market size has grown rapidly in recent years. It will grow from $0.75 billion in 2023 to $0.86 billion in 2024 at a compound annual growth rate (CAGR) of 14.5%. The growth during the historic period can be attributed to several factors, increased demand for PET scans, urbanization, rising disposable income, the need for accurate cancer diagnosis, and an increased emphasis on early detection.

The prostrate cancer nuclear medicine diagnostics market size is expected to see rapid growth in the next few years. It will grow to $1.49 billion in 2028 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to several factors, the rising prevalence of prostate cancer, increasing demand for positron emission tomography, growing awareness about environmental sustainability, the increasing frequency of cancers, and the ongoing digital transformation. Major trends expected during this period include product innovation, technological advancements, progress in nuclear medicine imaging, improvements in radiopharmaceuticals and imaging methods, and the development of innovative radiopharmaceuticals.

The anticipated increase in prostate cancer prevalence is expected to drive the expansion of the prostate cancer nuclear medicine diagnostics market. Prostate cancer, a type of cancer occurring in the prostate gland, is influenced by factors such as aging, lifestyle shifts, and genetic predispositions. Nuclear medicine diagnostics for prostate cancer offer crucial insights enabling clinicians to administer more accurate, efficient, and personalized treatment to patients. For instance, in January 2024, the American Cancer Society reported approximately 2.99 million new cases of prostate cancer and 35,250 deaths attributed to the disease. Additionally, in 2021, the National Cancer Institute recorded a rate of 116.5 new cases per 100,000 men annually. Thus, the increasing prevalence of prostate cancer is a significant driver for the prostate cancer nuclear medicine diagnostics market.

Key players in the prostate cancer nuclear medicine diagnostics sector are actively innovating diagnostic imaging technologies and securing approvals from the US Food and Drug Administration (FDA). FDA clearance ensures healthcare providers and patients have access to safe and effective diagnostic tests for various medical conditions. For example, in March 2022, Novartis, a Swiss pharmaceutical company, introduced Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for treating adult patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) that expresses prostate-specific membrane antigen-positive (PSMA-positive). Pluvicto combines a targeting compound (ligand) with a therapeutic radioisotope, delivering precise cancer treatment to prostate cancer cells expressing PSMA.

In March 2023, Life Healthcare Group, a South African healthcare company, acquired TheraMed Nuclear to enhance its diagnostic imaging services, particularly in detecting and treating diseases such as organ dysfunction and cancer. TheraMed Nuclear, based in South Africa, specializes in prostate cancer nuclear medicine diagnostics.

Major companies operating in the prostate cancer nuclear medicine diagnostics market are Cardinal Health, General Electric, Bayer AG , Novartis AG, Siemens Healthineers AG, GE Healthcare, Lantheus, CURIUM PHARMA, Telix Pharmaceuticals Ltd., Eckert & Ziegler AG, Point Biopharma Global Inc., Point Biopharma, Alliance Medical Ltd., SHINE Medical Technologies LLC , PETNET Solution, NorthStar Medical Radioisotopes LLC, Global Medical Solutions LLC , Isotope Technologies Garching (ITG), Jubilant Pharma Limited, Blue Earth Diagnostics Inc., Institute of Isotopes Co. Ltd. , Radiopharm Theranostics, Bracco Diagnostic Inc., NCM-USA LLC, ABX Advanced Biochemical Compounds GmbH

North America was the largest region in the prostrate cancer nuclear medicine diagnostics market in 2023. The regions covered in the prostate cancer nuclear medicine diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the prostate cancer nuclear medicine diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The prostate cancer nuclear medicine diagnostics market includes revenues earned by entities by bone scans, prostate-specific membrane antigen (PSMA) PET scan, bone scintigraphy, and CT scans. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prostate Cancer Nuclear Medicine Diagnostics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on prostate cancer nuclear medicine diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prostate cancer nuclear medicine diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The prostate cancer nuclear medicine diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Single Photon Emission Computed Tomography (SPECT); Photon Emission Computed Tomography (PET)
  • 2) By Test Type: Preliminary Tests; Confirmatory Tests
  • 3) By End User: Hospitals; Clinics; Other End Users
  • Companies Mentioned: Cardinal Health; General Electric; Bayer AG; Novartis AG; Siemens Healthineers AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Prostate Cancer Nuclear Medicine Diagnostics Market Characteristics

3. Prostate Cancer Nuclear Medicine Diagnostics Market Trends And Strategies

4. Prostate Cancer Nuclear Medicine Diagnostics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size and Growth

  • 5.1. Global Prostate Cancer Nuclear Medicine Diagnostics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Prostate Cancer Nuclear Medicine Diagnostics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Prostate Cancer Nuclear Medicine Diagnostics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Prostate Cancer Nuclear Medicine Diagnostics Market Segmentation

  • 6.1. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Single Photon Emission Computed Tomography (SPECT)
  • Photon Emission Computed Tomography (PET)
  • 6.2. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Preliminary Tests
  • Confirmatory Tests
  • 6.3. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Other End Users

7. Prostate Cancer Nuclear Medicine Diagnostics Market Regional And Country Analysis

  • 7.1. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market

  • 8.1. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Prostate Cancer Nuclear Medicine Diagnostics Market

  • 9.1. China Prostate Cancer Nuclear Medicine Diagnostics Market Overview
  • 9.2. China Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Prostate Cancer Nuclear Medicine Diagnostics Market

  • 10.1. India Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Prostate Cancer Nuclear Medicine Diagnostics Market

  • 11.1. Japan Prostate Cancer Nuclear Medicine Diagnostics Market Overview
  • 11.2. Japan Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Prostate Cancer Nuclear Medicine Diagnostics Market

  • 12.1. Australia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market

  • 13.1. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market

  • 14.1. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market Overview
  • 14.2. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market

  • 15.1. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market Overview
  • 15.2. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Prostate Cancer Nuclear Medicine Diagnostics Market

  • 16.1. UK Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Prostate Cancer Nuclear Medicine Diagnostics Market

  • 17.1. Germany Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Prostate Cancer Nuclear Medicine Diagnostics Market

  • 18.1. France Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Prostate Cancer Nuclear Medicine Diagnostics Market

  • 19.1. Italy Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Prostate Cancer Nuclear Medicine Diagnostics Market

  • 20.1. Spain Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market

  • 21.1. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market Overview
  • 21.2. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Prostate Cancer Nuclear Medicine Diagnostics Market

  • 22.1. Russia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Prostate Cancer Nuclear Medicine Diagnostics Market

  • 23.1. North America Prostate Cancer Nuclear Medicine Diagnostics Market Overview
  • 23.2. North America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Prostate Cancer Nuclear Medicine Diagnostics Market

  • 24.1. USA Prostate Cancer Nuclear Medicine Diagnostics Market Overview
  • 24.2. USA Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Prostate Cancer Nuclear Medicine Diagnostics Market

  • 25.1. Canada Prostate Cancer Nuclear Medicine Diagnostics Market Overview
  • 25.2. Canada Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Prostate Cancer Nuclear Medicine Diagnostics Market

  • 26.1. South America Prostate Cancer Nuclear Medicine Diagnostics Market Overview
  • 26.2. South America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market

  • 27.1. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market

  • 28.1. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market Overview
  • 28.2. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Prostate Cancer Nuclear Medicine Diagnostics Market

  • 29.1. Africa Prostate Cancer Nuclear Medicine Diagnostics Market Overview
  • 29.2. Africa Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Landscape And Company Profiles

  • 30.1. Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Landscape
  • 30.2. Prostate Cancer Nuclear Medicine Diagnostics Market Company Profiles
    • 30.2.1. Cardinal Health
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. General Electric
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Bayer AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Novartis AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Siemens Healthineers AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Prostate Cancer Nuclear Medicine Diagnostics Market Other Major And Innovative Companies

  • 31.1. GE Healthcare
  • 31.2. Lantheus
  • 31.3. CURIUM PHARMA
  • 31.4. Telix Pharmaceuticals Ltd.
  • 31.5. Eckert & Ziegler AG
  • 31.6. Point Biopharma Global Inc.
  • 31.7. Point Biopharma
  • 31.8. Alliance Medical Ltd.
  • 31.9. SHINE Medical Technologies LLC
  • 31.10. PETNET Solution
  • 31.11. NorthStar Medical Radioisotopes LLC
  • 31.12. Global Medical Solutions LLC
  • 31.13. Isotope Technologies Garching (ITG)
  • 31.14. Jubilant Pharma Limited
  • 31.15. Blue Earth Diagnostics Inc.

32. Global Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Benchmarking

33. Global Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Prostate Cancer Nuclear Medicine Diagnostics Market

35. Prostate Cancer Nuclear Medicine Diagnostics Market Future Outlook and Potential Analysis

  • 35.1 Prostate Cancer Nuclear Medicine Diagnostics Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Prostate Cancer Nuclear Medicine Diagnostics Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Prostate Cancer Nuclear Medicine Diagnostics Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer